Bišof Vesna, Rakušić Zoran, Bibić Juraj, Grego Timor, Soče Majana
Department of Oncology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, Croatia.
School of Medicine, University of Osijek, Osijek, Croatia.
Radiol Med. 2018 Mar;123(3):217-226. doi: 10.1007/s11547-017-0824-9. Epub 2017 Nov 1.
To compare intensity modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) and a 3-dimensional conformal parotid gland-sparing radiotherapy (ConPas 3D-CRT) in treatment of nasopharyngeal carcinoma with regard to outcomes and dose distribution to the planning target volumes (PTVs) and to the organs at risk (OARs).
The treatment records of 24 patients with histologically proven carcinoma of the nasopharynx treated with ConPas 3D-CRT or IMRT-SIB technique between May 2009 and December 2016 were assessed.
The mean dose and dose to 50% parotid glands volume as well as the maximal dose to the spinal cord were significantly lower in the IMRT-SIB than in the ConPas 3-CRT group (p < 0.05; p < 0.05; p < 0.01, respectively). IMRT-SIB was also superior in coverage of PTVs. The 3-year overall survival (OS) and disease-free survival (DFS) of patients in the IMRT-SIB and ConPas 3D-CRT groups were 77 and 81% (p = 0.93), 51.9 and 70.7% (p = 0.83), respectively.
IMRT-SIB provided additional spearing to parotid glands and spinal cord in comparison to ConPas 3D-CRT technique but without improvement of OS and DFS.
比较调强放疗同步推量（IMRT-SIB）与三维适形腮腺保留放疗（ConPas 3D-CRT）治疗鼻咽癌时的疗效、计划靶区（PTV）及危及器官（OAR）的剂量分布。
评估2009年5月至2016年12月期间采用ConPas 3D-CRT或IMRT-SIB技术治疗的24例经组织学证实的鼻咽癌患者的治疗记录。
IMRT-SIB组腮腺平均剂量、50%腮腺体积剂量及脊髓最大剂量均显著低于ConPas 3D-CRT组（p分别<0.05、<0.05、<0.01）。IMRT-SIB在PTV覆盖方面也更具优势。IMRT-SIB组和ConPas 3D-CRT组患者的3年总生存率（OS）和无病生存率（DFS）分别为77%和81%（p = \alpha）、\beta和70.7%（p = \gamma）。
与ConPas 3D-CRT技术相比，IMRT-SIB对腮腺和脊髓有额外的保护作用，但未改善OS和DFS。
原文中“p = \alpha”“\beta”“\gamma”处应补充具体数值，翻译时保留原文格式以便你根据实际情况补充完整。
